Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

Salvage radiotherapy (SRT) provides effective biochemical control for patients with prostate cancer who have prostate specific antigen (PSA) failure after radical prostatectomy. However, the effect of SRT on long-term clinical outcomes remains unknown. Therefore, we report the natural history of pat...

Full description

Saved in:
Bibliographic Details
Published in:Hong Kong medical journal = Xianggang yi xue za zhi 2018-06, Vol.24 (3), p.218-225
Main Authors: Lee, E K, Mui, W H, Chan, A W, Tung, Y, Wong, F C
Format: Article
Language:English
Subjects:
Aged
Androgens
Cancer surgery
Cancer therapies
Confidence intervals
Disease Progression
Hong Kong - epidemiology
Humans
Male
Metastasis
Middle Aged
Multivariate analysis
Neoplasm Metastasis
Neoplasm Recurrence, Local - radiotherapy
Patients
Prostate - pathology
Prostate cancer
Prostate-Specific Antigen - blood
Prostatectomy - adverse effects
Prostatic Neoplasms - mortality
Prostatic Neoplasms - radiotherapy
Prostatic Neoplasms - surgery
Radiation therapy
Radiotherapy Dosage
Salvage Therapy
Surgery
Survival Analysis
Treatment Outcome
Urological surgery
Variables
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Salvage radiotherapy (SRT) provides effective biochemical control for patients with prostate cancer who have prostate specific antigen (PSA) failure after radical prostatectomy. However, the effect of SRT on long-term clinical outcomes remains unknown. Therefore, we report the natural history of patients treated with SRT. We identified 84 Chinese patients with prostate cancer treated with SRT to the prostatic fossa alone during 2006-2017 at Tuen Mun Hospital, Hong Kong. Survival was calculated using Kaplan-Meier method. Log-rank test and Cox regression were used to determine significance of clinical parameters with outcomes. Median SRT dose given was 70 Gy (range, 64-76 Gy). Median pre-SRT PSA level was 0.4 ng/mL (0.2-7.4 ng/mL). After SRT, 47 (56%) patients had undetectable (
ISSN:1024-2708
2226-8707
DOI:10.12809/hkmj176888